RMD · ResMed Inc.
$224.092026-05-17Sector: Healthcare; Industry: Medical - Instruments & Supplies; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$217
-3.2% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($188 · $226) Analysts Range ($265 · $345) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2022.Q2 | $3.2B | — | 30.1% | 45.0% | $529MM | −$258MM | $270MM | 5.6% | — | 12.4% | $4.3B | $3.23 | — |
| 2023.Q2 | $3.6B | 11.9% | 29.7% | 19.0% | $861MM | −$1.8B | −$917MM | 7.7% | — | 16.8% | $6.0B | $5.30 | — |
| 2024.Q2 | $4.2B | 18.0% | 28.5% | 18.9% | $977MM | −$242MM | $734MM | 7.6% | — | 15.9% | $6.3B | $6.10 | — |
| 2025.Q2 | $4.7B | 10.9% | 30.0% | 18.6% | $1.1B | $97MM | $1.2B | 8.7% | — | 18.2% | $6.3B | $6.94 | — |
| 2026.Q2 | $5.4B | 15.2% | 36.0% | 18.3% | $1.6B | −$116MM | $1.5B | 8.3% | — | 24.6% | $6.6B | $10.11 | 17.0 |
| italics below = DCF projection · 10yr Rev CAGR: 8% |
| 2027.Q2 | $5.9B | +8.8% | 35.0% | 18.5% | $1.7B | −$599MM | $1.1B | 8.1% | $993MM | 24.1% | $7.2B | $10.70 | 20.9 |
| 2028.Q2 | $6.3B | +7.2% | 35.0% | 18.6% | $1.8B | −$550MM | $1.2B | 8.2% | $1.1B | 23.8% | $7.8B | $11.44 | 19.6 |
| 2029.Q2 | $6.7B | +7.3% | 35.0% | 18.8% | $1.9B | −$619MM | $1.3B | 8.2% | $1.0B | 23.6% | $8.4B | $12.25 | 18.3 |
| 2030.Q2 | $7.4B | +9.8% | 35.0% | 19.0% | $2.1B | −$933MM | $1.2B | 8.3% | $852MM | 23.7% | $9.3B | $13.42 | 16.7 |
| 2031.Q2 | $8.3B | +11.7% | 35.0% | 19.1% | $2.3B | −$1.3B | $1.1B | 8.3% | $728MM | 23.5% | $10.6B | $14.96 | 15.0 |
|
| Term. Yr+ | $12.2B | 4.1% | 28.9% | 20.0% | $2.8B | −$647MM | $2.2B | 8.6% | $21.6B | 17.8% | — | — | — |
Active scenario IV: $217 (-3.2% vs market)